WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies, Inc. has successfully closed its public offering of securities, generating aggregate gross proceeds of $3.2 million. The offering, which was finalized on June 18, 2026, consisted of 4,000,000 shares of common stock priced at $0.80 per share. WallachBeth Capital, LLC served as the sole placement agent for this transaction, facilitating the process under a registration statement declared effective by the Securities and Exchange Commission.

bioAffinity Technologies, based in Jersey City, New Jersey, is a biotechnology firm dedicated to developing noninvasive and accurate diagnostic tests for early-stage lung cancer and other lung diseases. The company's focus on innovative solutions addresses a critical need in the healthcare sector, as early detection significantly improves treatment outcomes for patients. The funds raised through this offering are expected to support the company's ongoing research and development efforts, as well as enhance its operational capabilities.

The biotechnology sector has seen a surge in public offerings as companies seek to capitalize on the growing demand for advanced medical diagnostics and treatments. Investors are increasingly interested in companies that can demonstrate potential for significant impact in the healthcare landscape, particularly those focused on oncology and respiratory diseases. bioAffinity's strategic positioning within this dynamic market, combined with its innovative product pipeline, may attract further interest from institutional investors looking for opportunities in the biotech space.

The successful completion of this offering reflects the broader trend of increasing capital flows into the biotechnology sector, where companies are leveraging public markets to fund their growth strategies. As the demand for effective diagnostic solutions continues to rise, firms like bioAffinity Technologies are well-positioned to benefit from the increased focus on early detection and personalized medicine. The capital raised will likely enhance bioAffinity's ability to navigate the competitive landscape and advance its mission of improving patient outcomes through innovative diagnostics.

Looking ahead, the biotechnology sector is expected to remain robust, with continued investor interest driven by advancements in technology and a growing emphasis on healthcare innovation. The successful public offering by bioAffinity Technologies may serve as a catalyst for similar companies in the sector, encouraging them to pursue public financing as a means to accelerate their development efforts and expand their market presence.